These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
189 related articles for article (PubMed ID: 15728323)
1. Does Campylobacter jejuni infection elicit "demyelinating" Guillain-Barré syndrome? Berciano J; Illa I Neurology; 2005 Feb; 64(4):766-7; author reply 766-7. PubMed ID: 15728323 [No Abstract] [Full Text] [Related]
2. Does Campylobacter jejuni infection elicit "demyelinating" Guillain-Barre syndrome? Kuwabara S; Ogawara K; Misawa S; Koga M; Mori M; Hiraga A; Kanesaka T; Hattori T; Yuki N Neurology; 2004 Aug; 63(3):529-33. PubMed ID: 15304587 [TBL] [Abstract][Full Text] [Related]
3. A family with Campylobacter enteritis: anti-GD1a antibody with/without Guillain-Barré syndrome. Hirano M; Kusunoki S; Asai H; Tonomura Y; Morita D; Ueno S Neurology; 2003 May; 60(10):1719-20. PubMed ID: 12771281 [No Abstract] [Full Text] [Related]
4. Subclass IgG to motor gangliosides related to infection and clinical course in Guillain-Barré syndrome. Jacobs BC; Koga M; van Rijs W; Geleijns K; van Doorn PA; Willison HJ; Yuki N J Neuroimmunol; 2008 Feb; 194(1-2):181-90. PubMed ID: 18178257 [TBL] [Abstract][Full Text] [Related]
5. The relationship of Campylobacter jejuni infection and the development of Guillain-Barré syndrome. Tsang RS Curr Opin Infect Dis; 2002 Jun; 15(3):221-8. PubMed ID: 12015454 [TBL] [Abstract][Full Text] [Related]
7. Tolerance to self gangliosides is the major factor restricting the antibody response to lipopolysaccharide core oligosaccharides in Campylobacter jejuni strains associated with Guillain-Barré syndrome. Bowes T; Wagner ER; Boffey J; Nicholl D; Cochrane L; Benboubetra M; Conner J; Furukawa K; Furukawa K; Willison HJ Infect Immun; 2002 Sep; 70(9):5008-18. PubMed ID: 12183547 [TBL] [Abstract][Full Text] [Related]
8. Guillain Barré Syndrome is induced in Non-Obese Diabetic (NOD) mice following Campylobacter jejuni infection and is exacerbated by antibiotics. St Charles JL; Bell JA; Gadsden BJ; Malik A; Cooke H; Van de Grift LK; Kim HY; Smith EJ; Mansfield LS J Autoimmun; 2017 Feb; 77():11-38. PubMed ID: 27939129 [TBL] [Abstract][Full Text] [Related]
9. Is Campylobacter lipopolysaccharide bearing a GD3 epitope essential for the pathogenesis of Guillain-Barré syndrome? Yuki N; Koga M; Hirata K Acta Neurol Scand; 2000 Aug; 102(2):132-4. PubMed ID: 10949532 [TBL] [Abstract][Full Text] [Related]
10. Anti-ganglioside antibodies in patients with Guillain-Barré syndrome and Campylobacter jejuni infection. Rees JH; Gregson NA; Hughes RA J Infect Dis; 1995 Aug; 172(2):605-6. PubMed ID: 7622918 [No Abstract] [Full Text] [Related]
12. Prognosis in the acute motor axonal form of Guillain-Barré syndrome. Gabriel CM J Neurol Neurosurg Psychiatry; 2005 May; 76(5):622. PubMed ID: 15834016 [No Abstract] [Full Text] [Related]
13. Hyperreflexia in axonal Guillain-Barré syndrome subsequent to Campylobacter jejuni enteritis. Kuwabara S; Nakata M; Sung JY; Mori M; Kato N; Hattori T; Koga M; Yuki N J Neurol Sci; 2002 Jul; 199(1-2):89-92. PubMed ID: 12084449 [TBL] [Abstract][Full Text] [Related]
14. Lipopolysaccharides in the development of the Guillain-Barré syndrome and Miller Fisher syndrome forms of acute inflammatory peripheral neuropathies. Prendergast MM; Moran AP J Endotoxin Res; 2000; 6(5):341-59. PubMed ID: 11521055 [TBL] [Abstract][Full Text] [Related]
15. Guillain-Barré syndrome in northern China. Relationship to Campylobacter jejuni infection and anti-glycolipid antibodies. Ho TW; Mishu B; Li CY; Gao CY; Cornblath DR; Griffin JW; Asbury AK; Blaser MJ; McKhann GM Brain; 1995 Jun; 118 ( Pt 3)():597-605. PubMed ID: 7600081 [TBL] [Abstract][Full Text] [Related]
16. [A case of Guillain-Barré syndrome after Campylobacter jejuni enterocolitis: anti-ganglioside antibody levels with or without Guillain-Barré syndrome]. Watanabe H; Shindo K; Nakamura Y; Nagamatsu M; Shiozawa Z; Kusunoki S Rinsho Shinkeigaku; 2001 Sep; 41(9):625-7. PubMed ID: 11968750 [TBL] [Abstract][Full Text] [Related]
17. Preceding infections and anti-ganglioside antibodies in patients with Guillain-Barré syndrome: a single centre prospective case-control study. Sinha S; Prasad KN; Jain D; Pandey CM; Jha S; Pradhan S Clin Microbiol Infect; 2007 Mar; 13(3):334-7. PubMed ID: 17391394 [TBL] [Abstract][Full Text] [Related]
18. Molecular mimicry between gangliosides and lipopolysaccharides of Campylobacter jejuni isolated from patients with Guillain-Barré syndrome and Miller Fisher syndrome. Yuki N J Infect Dis; 1997 Dec; 176 Suppl 2():S150-3. PubMed ID: 9396700 [TBL] [Abstract][Full Text] [Related]
19. T cell recognition of a non-protein antigen preparation of Campylobacter jejuni in patients with Guillain-Barré syndrome. Cooper JC; Hughes S; Ben-Smith A; Savage CO; Winer JB J Neurol Neurosurg Psychiatry; 2002 Mar; 72(3):413-4. PubMed ID: 11861714 [No Abstract] [Full Text] [Related]
20. Recognition characteristics of monoclonal antibodies that are cross-reactive with gangliosides and lipooligosaccharide from Campylobacter jejuni strains associated with Guillain-Barré and Fisher syndromes. Houliston RS; Yuki N; Hirama T; Khieu NH; Brisson JR; Gilbert M; Jarrell HC Biochemistry; 2007 Jan; 46(1):36-44. PubMed ID: 17198373 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]